QT monitoring in chemotherapy

Figure 1. Serial electrocardiograms demonstrating QTc changes and arrhythmia. (A) Prior ECG: Baseline tracing showing sinus rhythm with a corrected QT interval (QTc) of 455 ms. (B) ECG at Admission: Sinus rhythm with QTc prolongation to 487 ms. (C) Telemetry Recording: Episode of polymorphic ventricular tachycardia consistent with torsades de pointes, occurring during hospitalization. (D) Follow-up ECG: Sinus rhythm restored with QTc shortened to 451 ms after clinical intervention.

Figure 2. Drug classes associated with QT interval prolongation and risk of torsades de pointes. This figure lists common medications that can prolong the QT interval and increase the risk of torsades de pointes, grouped by therapeutic class. These include antipsychotics (e.g., risperidone, haloperidol), antiemetics (ondansetron, promethazine), antiarrhythmics (such as amiodarone, dofetilide, sotalol), antimicrobials (including voriconazole, ciprofloxacin, moxifloxacin, erythromycin, and clarithromycin), and analgesics (methadone). Drugs highlighted in brown represent those with a higher or more frequent association with QT prolongation.

Figure 3. Ventricular action potential (VAP) and ionic currents across phases. (A) Ventricular Action Potential (VAP): Schematic representation of the duration of ventricular activation and recovery, including depolarization and repolarization. Key ionic movements include rapid inflow of Na + and Ca2 + and outflow of K + ions. (B–H) Phases of VAP with Voltage-Time Relationship and Major Ionic Currents: (B) Phase 4 (Resting Membrane Potential): Stable resting potential maintained by inward rectifier K + current (Ik1) and gap junctions. (C,D) Phase 0 (Rapid Depolarization): Sudden increase in membrane potential due to rapid Na + influx through fast Na + channels; minor contribution from Ca2 + entry. (E) Phase 1 (Initial Repolarization): Transient outward K + current (IKS) and slow delayed rectifier K + channels initiate early repolarization. (F) Phase 2 (Plateau): Balance between inward Ca2 + current (ICa-L) and outward K + currents maintains prolonged depolarization. (G) Phase 3 (Rapid Repolarization): Dominated by activation of rapid delayed rectifier K + channels and closure of Ca2 + channels, restoring negative potential. (H) Phase 4 (Return to Resting State): Membrane potential returns…

Figure 4. QT interval measurement and correction methods. (A) Normal ECG waveform illustrating P, QRS, and T waves with baseline reference. (B) Standard QT measurement from the onset of the Q wave to the end of the T wave. (C) Tangent method for QT measurement, where the end of the T wave is determined by the intersection of the tangent to the steepest slope of the terminal T wave and the baseline. (D) Comparison of commonly used QT correction formulas: Bazett, Fridericia, Framingham, and Hodges. Each formula is shown with its mathematical expression, classification as linear or nonlinear, and unique limitations, including overcorrection at high heart rates and undercorrection at low heart rates.

Figure 5. QTc monitoring and management algorithms for tyrosine kinase inhibitors. Flowcharts outlining recommended steps for QT interval monitoring and management in patients receiving QT-prolonging cancer therapies. (A) General approach for high-risk chemotherapy, including baseline ECG, serum potassium, and magnesium assessment, with correction of abnormalities prior to treatment initiation. (B) Vandetanib protocol: start at 300 mg daily if QTc <450 ms and electrolytes are normal; repeat ECG and labs at 2–4 weeks and every 3 months; discontinue for persistent QTc >500 ms. (C) Vemurafenib protocol: initiate 960 mg twice daily if QTc <500 ms; monitor ECG and electrolytes at baseline, after 15 days, and monthly; withhold or discontinue for QTc >500 ms or significant increases from baseline. (D) Nilotinib protocol: start 400 mg twice daily if QTc <480 ms; monitor ECG at baseline, day 7, and periodically; withhold or reduce dose for QTc prolongation, and discontinue if QTc ≥480 ms persists.

Figure 6. QTc monitoring and patient care strategies for arsenic trioxide therapy. (A) Algorithm for initiating and monitoring arsenic trioxide treatment based on QTc interval and electrolyte status. Therapy begins if QTc <500 ms and electrolytes are normal, with weekly ECG and twice-weekly electrolyte checks. QTc >500 ms or symptomatic arrhythmia prompts correction of abnormalities, hospitalization for cardiac monitoring, and temporary drug hold until QTc <460 ms and symptoms resolve.(B) Patient care improvement strategies to reduce QT-related risk: consistent data collection using the tangent method and Fridericia formula for QT correction; identification and correction of electrolyte disturbances (K+, Mg2+) and avoidance of other QT-prolonging drugs; and adherence to cardiac monitoring guidelines for high-risk chemotherapy per FDA recommendations.